CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-283/S-002

Final Printed Labeling
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of valsartan on blood pressure.

**Pharmacokinetics**

Valsartan peak plasma concentration is reached 2 to 4 hours after dosing. Valsartan shows bi-exponential decay kinetics following intravenous administration, with an average elimination half-life of about 6 hours. Absolute bioavailability for Diovan is about 25% (range 10%–35%). Food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%. AUC and Cmax values of valsartan increase approximately linearly with increasing dose over the clinical dosing range. Valsartan does not accumulate appreciably in plasma following repeated administration.

**Metabolism and Elimination**

Valsartan, when administered as an oral solution, is primarily recovered in feces (about 83% of dose) and urine (about 13% of dose). The recovery is mainly as unchanged drug, with only about 20% of dose recovered as metabolites. The primary metabolite, accounting for about 9% of dose, is valeryl 4-hydroxy valsartan. The enzyme(s) responsible for valsartan metabolism have not been identified but do not seem to be CYP 450 isozymes.

Following intravenous administration, plasma clearance of valsartan is about 2 L/h and its renal clearance is 0.82 L/h (about 30% of total clearance).

**Distribution**

The steady state volume of distribution of valsartan after intravenous administration is small (17 L), indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (95%), mainly serum albumin.

**Special Populations**

- **Pediatric:** The pharmacokinetics of valsartan have not been investigated in patients <18 years of age.
- **Geriatric:** Exposure (measured by AUC) to valsartan is higher by 70% and the half-life is longer by 35% in the elderly than in the young. No dosage adjustment is necessary (see DOSAGE AND ADMINISTRATION).
- **Gender:** Pharmacokinetics of valsartan does not differ significantly between males and females.
- **Renal Insufficiency:** There is no apparent correlation between renal function (measured by creatinine clearance) and exposure (measured by AUC) to valsartan in patients with different degrees of renal impairment. Consequently, dose adjustment is not required in patients with mild-to-moderate renal dysfunction. No studies have been performed in patients with severe impairment of renal function (creatinine clearance < 10 mL/min). Valsartan is not removed from the plasma by hemodialysis. In the case of severe renal disease, exercise care with dosing of valsartan (see DOSAGE AND ADMINISTRATION).
- **Hepatic Insufficiency:** On average, patients with mild-to-moderate chronic liver disease have twice the exposure (measured by AUC values) to valsartan of healthy volunteers (matched by age, sex, and weight). In general, no dosage adjustment is needed in patients with mild-to-moderate liver disease. Care should be exercised in patients with liver disease (see DOSAGE AND ADMINISTRATION).

**Pharmacodynamics and Clinical Effects**

Valsartan inhibits the pressor effect of angiotensin II infusions. An oral dose of 80 mg inhibits the pressor effect by about 80% at peak with approximately 30% inhibition persisting for 24 hours. No information on the effect of larger doses is available.

Removal of the negative feedback of angiotensin II causes a 2- to 3-fold rise in plasma renin and consequent rise in angiotensin II plasma concentration in hypertensive patients. Minimal decreases in plasma aldosterone were observed after administration of valsartan; very little effect on serum potassium was observed.

In multiple-dose studies in hypertensive patients with stable renal insufficiency and patients with renovascular hypertension, valsartan had no clinically significant effects on glomerular filtration rate, filtration fraction, creatinine clearance, or renal plasma flow.

In multiple-dose studies in hypertensive patients, valsartan had no notable effects on total cholesterol, fasting triglycerides, fasting serum glucose, or uric acid.

The antihypertensive effects of Diovan were demonstrated principally in 7 placebo-controlled, 4- to 12-week trials (one in patients over 65) of dosages from 10 to 320 mg/day in patients with baseline diastolic blood pressures of 95-115. The studies allowed comparison of once-daily and twice-daily
regimens of 160 mg/day; comparison of peak and trough effects; comparison (in pooled data) of response by gender, age, and race; and evaluation of incremental effects of hydrochlorothiazide.

Administration of valsartan to patients with essential hypertension results in a significant reduction of sitting, supine, and standing systolic and diastolic blood pressure, usually with little or no orthostatic change. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs at approximately 2 hours, and maximum reduction of blood pressure is achieved within 2 hours. The antihypertensive effect persists for 24 hours after dosing, but there is a decrease from peak effect at lower doses (40 mg) presumably reflecting loss of inhibition of angiotensin II. At higher doses, however (160 mg), there is little difference in peak and trough effect. During repeated dosing, the reduction in blood pressure with any dose is substantially present within 2 weeks, and maximal reduction is generally attained after 4 weeks. In long-term follow-up studies (without placebo control), the effect of valsartan appeared to be maintained for up to 2 years. The antihypertensive effect was independent of age, gender or race. The latter finding regarding race is based on pooled data and should be viewed with caution, because antihypertensive drugs that affect the renin-angiotensin system (that is, ACE inhibitors and angiotensin-II blockers) have generally been found to be less effective in low-renin hypertensives (frequently blacks) than in high-renin hypertensives (frequently whites). In pooled, randomized, controlled trials of Diovan that included a total of 140 blacks and 830 whites, valsartan and an ACE-inhibitor control were generally at least as effective in blacks as whites. The explanation for this difference from previous findings is unclear.

Abrupt withdrawal of valsartan has not been associated with a rapid increase in blood pressure.

The blood pressure lowering effect of valsartan and thiazide-type diuretics are approximately additive.

The 7 studies of valsartan monotherapy included over 2000 patients randomized to various doses of valsartan and about 800 patients randomized to placebo. Doses below 80 mg were not consistently distinguished from those of placebo at trough, but doses of 80, 160 and 320 mg produced dose-related decreases in systolic and diastolic blood pressure, with the difference from placebo of approximately 6/3-5 mm Hg at 80-160 mg and 12/5 mm Hg at 320 mg. In a controlled trial the addition of HCTZ to valsartan 80 mg resulted in additional lowering of systolic and diastolic blood pressure by approximately 6/3 and 12/5 mm Hg for HCTZ, respectively, compared to valsartan 80 mg alone.

Patients with an inadequate response to 80 mg once daily were titrated to either 160 mg once daily or 80 mg twice daily, which resulted in a comparable response in both groups.

In controlled trials, the antihypertensive effect of once-daily valsartan 80 mg was similar to that of once-daily enalapril 20 mg or once-daily lisinopril 10 mg.

There was essentially no change in heart rate in valsartan-treated patients in controlled trials.

INDICATIONS AND USAGE
Diovan is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

CONTRAINDICATIONS
Diovan is contraindicated in patients who are hypersensitive to any component of this product.

WARNINGS
Fetal/Neonatal Morbidity and Mortality
Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been presented in the literature in patients who were taking angiotensin-converting enzyme inhibitors. When pregnancy is detected, Diovan should be discontinued as soon as possible.

The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios may be an indicator of fetal distress. Cerebrovascular disorders have been associated with fetal lamb contractures, craniolacunar deformity, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.

These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should advise the patient to discontinue the use of valsartan as soon as possible.

Rarer (probably less often than once in every thousand pregnancies), no alternative to a drug acting on the renin-angiotensin system will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intra-amniotic environment.

If oligohydramnios is observed, valsartan should be discontinued unless it is considered life-saving for the mother. Contractions stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.

No teratogenic effects were observed when valsartan was administered to pregnant mice and rats at oral doses up to 600 mg/kg/day and to pregnant rabbits at oral doses up to 10 mg/kg/day. However, significant decreases in fetal weight, pup birth weight, pup survival rates, and slight delays in developmental milestones were observed in studies in which parental rats were treated with valsartan at oral, maternally toxic (reduction in body weight gain and food consumption) doses of 600 mg/kg/day during organogenesis or late gestation and lactation. In rabbits, fetotoxicity (i.e., resorptions, litter loss, abortions, and low body weight) associated with maternal toxicity (mortality) was observed at doses of 5 and 10 mg/kg/day. The no observed adverse effect doses of 600, 200 and 2 mg/kg/day in mice, rats and rabbits represent 9, 6, and 0.1 times, respectively, the maximum recommended human dose on a mg/m² basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)

Hypotension in Volume- and/or Salt-Depleted Patients
Excessive reduction of blood pressure was rarely seen (0.1%) in patients with uncomplicated hypertension. In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. This condition should be corrected prior to administration of Diovan, or the treatment should start under close medical supervision.

If hypotension occurs, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.

PRECAUTIONS
General
Impaired Hepatic Function: As the majority of valsartan is eliminated in the bile, patients with mild-to-moderate hepatic impairment, including patients with biliary obstructive disorders, showed lower valsartan clearance (higher AUCs). Care should be exercised in administering Diovan to these patients.

Impaired Renal Function: As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe constrictive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with Diovan.

Studies of ACE inhibitors in patients with unilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. In a 4-day trial of valsartan in 12 patients with unilateral renal artery stenosis, no significant increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of Diovan in patients with unilateral or bilateral renal artery stenosis, but an effect similar to that seen with ACE inhibitors should be anticipated.

Information for Patients
Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to drugs that act on the renin-angiotensin system, and they should also be told that these consequences do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.
Drug Interactions
No clinically significant pharmacokinetic interactions were observed when valsartan was coadministered with amiodipine, atenolol, cimetidine, digoxin, furosemide, glibenclamide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone.

Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin.

CYP 450 Interactions: The enzyme(s) responsible for valsartan metabolism have not been identified but do not seem to be CYP 450 isozymes. The inhibitory or induction potential of valsartan on CYP 450 is also unknown.

Carcinogenesis, Mutagenesis, Impairment of Fertility
There was no evidence of carcinogenicity when valsartan was administered in the diet to mice and rats for up to 2 years at doses up to 180 and 200 mg/kg/day, respectively. These doses in mice and rats are about 2.6 and 6 times, respectively, the maximum recommended human dose on a mg/m² basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)

Mutagenicity assays did not reveal any valsartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with Salmonella (Ames) and E. coli; a gene mutation test with Chinese hamster V79 cells; a cytogenetic test with Chinese hamster ovary cells, and a rat micronucleus test.

Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a body surface area basis. (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)

Pregnancy Categories C (first trimester) and D (second and third trimesters)
See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Nursing Mothers
It is not known whether valsartan is excreted in human milk, but valsartan was excreted in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

Geriatric Use
In the controlled clinical trials of valsartan, 1214 (36.2%) of patients treated with valsartan were ≥65 years and 265 (7.9%) were ≥75 years. No overall difference in the efficacy of safety of valsartan was observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS
Diovan has been evaluated for safety in more than 4000 patients, including over 400 treated for over 6 months, and more than 160 for over 1 year. Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. The overall incidence of adverse experiences with Diovan was similar to placebo.

The overall frequency of adverse experiences was neither dose-related nor related to gender, age, race, or regimen. Discontinuation of therapy due to side effects was required in 2.3% of valsartan patients and 2.0% of placebo patients. The most common reasons for discontinuation of therapy with Diovan were headache and dizziness.

The adverse experiences that occurred in placebo-controlled clinical trials in at least 1% of patients treated with Diovan and at a higher incidence in valsartan (n=2315) than placebo (n=888) patients included viral infection (3% vs. 2%), fatigue (2% vs. 1%), and abdominal pain (2% vs. 1%).

Headache, dizziness, upper respiratory infection, cough, diarrhea, rhinitis, sinusitis, nausea, pharyngitis, edema, and arthralgia occurred at a more than 1% rate but at about the same incidence in placebo and valsartan patients.

In trials in which valsartan was compared to an ACE inhibitor with or without placebo, the incidence of dry cough was significantly greater in the ACE-inhibitor group (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%). In a 129-patient trial limited to patients who had had dry cough when they had previously received ACE inhibitors, the incidences of cough in patients who received valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively (p < 0.001).

Dose-related orthostatic effects were seen in less than 1% of patients. An increase in the incidence of dizziness was observed in patients treated with Diovan 320 mg (8%) compared to 10 to 160 mg (2% to 4%).

Diovan has been used concomitantly with hydrochlorothiazide without evidence of clinically important adverse interactions.

Other adverse experiences that occurred in controlled clinical trials of patients treated with Diovan >0.2% of valsartan patients) are listed below. It cannot be determined whether these events were causally related to Diovan.

Body as a Whole: Allergic reaction and anemia
Cardiovascular: Palpitations
Dermatologic: Pruritus and rash
Digestive: Constipation, dry mouth, dyspepsia, and flatulence
Musculoskeletal: Back pain, muscle cramps, and myalgia
Neurologic and Psychiatric: Anxiety, insomnia, paresthesia, and somnolence
Respiratory: Dyspnea
Special Senses: Vertigo
Urogenital: Impotence
Other reported events seen less frequently in clinical trials included chest pain, syncope, anorexia, vomiting, and angioedema.

Post-Marketing Experience
The following additional adverse reactions have been reported in post-marketing experience:

Hypersensitivity: There are rare reports of angioedema;

Digestive: Elevated liver enzymes and very rare reports of hepatitis;

Renal: Impaired renal function;

Clinical Laboratory Tests: Hyperkalemia;

Dermatologic: Alopecia.

Clinical Laboratory Test Findings
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Diovan.

Creatinine: Minor elevations in creatinine occurred in 0.8% of patients taking Diovan and 0.6% given placebo in controlled clinical trials.

Hemoglobin and Hematocrit: Greater than 20% decreases in hemoglobin and hematocrit were observed in 0.4% and 0.8%, respectively, of Diovan patients, compared with 0.1% and 0.1% in placebo-treated patients. One valsartan patient discontinued treatment for microcytic anemia.

Liver function tests: Occasional elevations (greater than 150%) of liver enzymes were observed in Diovan-treated patients. Three patients (0.1%) were treated with valsartan discontinued treatment for elevated liver enzymes.

Neutropenia: Neutropenia was observed in 1.9% of patients treated with Diovan and 0.8% of patients treated with placebo.

Serum Potassium: Greater than 20% increases in serum potassium were observed in 4.4% of Diovan-treated patients compared to 2.9% of placebo-treated patients.

OVERDOSAGE
Limited data are available related to overdosage in humans. The most likely manifestations of overdosage would be hypotension and tachycardia. Bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.

Valsartan is not removed from the plasma by hemodialysis.

Valsartan was without grossly observable adverse effects at single oral doses up to 2000 mg/kg in rats and up to 1000 mg/kg in marmosets except for salivation and diarrhea in the rat and vomiting in the marmoset at the highest dose (60 and 37 times, respectively, the maximum recommended human dose on a mg/m² basis). (Calculations assume an oral dose of 320 mg/day and a 60-kg patient.)

DOSAGE AND ADMINISTRATION
The recommended starting dose of Diovan is 80 mg or 160 mg once daily when
The mean difference in blood pressure between the 80 and 160 mg doses is -1.8/-1.2 mmHg.1

The following table summarizes safety data from Dr. Ganley's primary medical review of valsartan (under NDA 20-665).

| Table 35.7, Most Commonly Reported Adverse Events (≥ 1%) Based On Dose In Placebo-Controlled Trials |
|--------------------------------------------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Total Patients                                  | 20 (12%)                        | 36 (18%)        | 62 (18%)        | 121 (16%)       | 261 (18%)       | 70 (16%)        | 70 (16%)        | 140 (19%)       | 190 (21%)       |
| Patients with AEs                                | 11 (44%)                        | 14 (39%)        | 31 (41%)        | 63 (52%)        | 106 (40%)       | 28 (40%)        | 28 (40%)        | 50 (36%)        | 61 (32%)        |
| Headache                                         | 1 (6)                            | 3 (10)          | 5 (6)           | 12 (10)         | 21 (8)          | 4 (6)           | 4 (6)           | 9 (7)           | 10 (5)          |
| Diarrhea                                         | 1 (5)                            | 0 (0)           | 2 (3)           | 6 (5)           | 12 (4)          | 0 (0)           | 2 (3)           | 3 (2)           | 4 (2)           |
| Infection Viral                                  | 0 (0)                            | 0 (0)           | 0 (0)           | 1 (1)           | 2 (1)           | 0 (0)           | 0 (0)           | 1 (1)           | 2 (1)           |
| URT                                             | 1 (6)                            | 2 (6)           | 3 (4)           | 11 (9)          | 28 (11)         | 5 (7)           | 5 (7)           | 11 (10)         | 17 (9)          |
| Gastrointestinal                                | 1 (5)                            | 1 (3)           | 3 (4)           | 8 (7)           | 17 (6)          | 3 (4)           | 3 (4)           | 8 (7)           | 13 (7)          |
| Abdominal pain                                   | 1 (5)                            | 1 (3)           | 2 (3)           | 7 (6)           | 19 (7)          | 2 (3)           | 3 (4)           | 9 (8)           | 14 (8)          |
| Fatigue                                          | 0 (0)                            | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           |
| Rash                                             | 0 (0)                            | 0 (0)           | 1 (1)           | 6 (5)           | 19 (7)          | 0 (0)           | 1 (1)           | 6 (5)           | 11 (6)          |
| Nausea                                           | 1 (5)                            | 0 (0)           | 2 (3)           | 7 (6)           | 18 (7)          | 1 (1)           | 3 (4)           | 9 (8)           | 14 (8)          |
| Pneumonia                                        | 0 (0)                            | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           | 0 (0)           |

Headache and dizziness are perhaps increased at 320 mg, but there is not much suggestion of dose-related adverse effects below that dose.

Starting doses for other angiotensin receptor antagonists are shown in Table 1.

Table 1. Starting doses for various angiotensin receptor antagonists.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Start</th>
<th>Mean effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candesartan</td>
<td>16 mg</td>
<td>&gt;8/4 mmHg</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>150 mg</td>
<td>7/4 mmHg</td>
</tr>
<tr>
<td>Losartan</td>
<td>50 mg</td>
<td>6/4 mg</td>
</tr>
<tr>
<td>Telmesartan</td>
<td>40 mg</td>
<td>11/7 mg</td>
</tr>
</tbody>
</table>

With the proposed change, the mean effect of valsartan's starting dose would remain within the range of effect sizes seen with the starting doses of other angiotensin receptor antagonists.

The sponsor's proposed changes to the label are confined to the DOSAGE AND ADMINISTRATION section, as follows:

The recommended starting dose of Diovan is 80 mg or 160 mg once daily when used as monotherapy in patients who are not volume-depleted. Patients requiring greater reductions may be started at the higher dose. Diovan may be used over a dose range of 80 mg to 320 mg daily, administered once-a-day.

The antihypertensive effect is substantially present within 2 weeks and maximal reduction is generally attained after 4 weeks. If additional antihypertensive effect is required over the starting dose range, the dose may be increased to a maximum of

---

1 Curiously, however, the publication concludes "In clinical practice, valsartan 80 mg once daily is an appropriate starting dosage for most hypertensive patients."
used as monotherapy in patients who are not volume-depleted. Patients
requiring greater reductions may be started at the higher dose. Diovan may be
used over a dose range of 80 mg to 320 mg daily, administered once-a-day.

The antihypertensive effect is substantially present within 2 weeks and maximal
reduction is generally attained after 4 weeks. If additional antihypertensive
effect is required over the starting dosage range, the dose may be increased to
a maximum of 320 mg or a diuretic may be added. Addition of a diuretic has a
greater effect than dose increases beyond 80 mg.

No initial dosage adjustment is required for elderly patients, for patients with
mild or moderate renal impairment, or for patients with mild or moderate liver
insufficiency. Care should be exercised with dosing of Diovan in patients with
hepatic or severe renal impairment.

Diovan may be administered with other antihypertensive agents.
Diovan may be administered with or without food.

HOW SUPPLIED
Diovan is available as tablets containing valsartan 80 mg, 160 mg or 320 mg.
All strengths are packaged in bottles of 100 tablets and unit dose blister
packages. Tablets are debossed as follows:

80 mg Tablet - Pale red, almond-shaped with bevelled edges, debossed with
DV on one side and NVR on the other.
Bottles of 100 ..................................................NDC 0078-0358-05
Unit Dose (blister pack) .................................................NDC 0078-0358-06
Box of 100 (strips of 10)

160 mg Tablet - Grey-orange, almond-shaped with bevelled edges, debossed
with DX on one side and NVR on the other.
Bottles of 100 ..........................................................NDC 0078-0359-05
Unit Dose (blister pack) ..................................................NDC 0078-0359-06
Box of 100 (strips of 10)

320 mg Tablet - Dark greyish violet, almond-shaped with bevelled edges,
debossed with DXL on one side and NVR on the other.
Bottles of 100 ..........................................................NDC 0078-0360-05
Unit Dose (blister pack) ..................................................NDC 0078-0360-06
Box of 100 (strips of 10)

Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F).
[See USP controlled room temperature.]
Protect from moisture.
Dispense in tight container (USP).

REV: MARCH 2002

T2002-26
Printed in U.S.A.
89004206

© NOVARTIS

Distributed by
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936